natriuretic peptide

C-Type Natriuretic Peptide (CNP) (1-22), human acetate is an agonist of natriuretic peptide receptor B (NPR-B), an endothelial-derived relaxant and growth inhibitory factor. C-Type Natriuretic Peptide (CNP) (1-22), human acetate inhibits cAMP synthesis stimulated by histamine and 5-HT or directly by Forskolin.

C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide.

Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide hormone synthesized by ventricular cardiomyocytes as a result of myocardial cell stretching (cardiomyocyte distension)[1].

Dendroaspis Natriuretic Peptide, a vasodilator peptide, is derived from animal venom [1].

Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is an isoform of rat brain natriuretic peptide extracted from rat heart, exhibiting significant hypotensive and natriuretic effects [1].

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) that exerts endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide holds promise for cardiovascular diseases research.

Brain Natriuretic Peptide (BNP) (1-32), rat is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).Brain natriuretic peptide (type B natriuretic peptide) was origin

Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)), a peptide hormone produced by the atrial myocardium, plays a critical role in the regulation of blood pressure, fluid balance, and electrolyte homeostasis [1] [2].

CNP, a member of the natriuretic peptide family, was first identified in porcine brain and later found in other mammals as well as non-mammals. Processing of the CNP precursor gives rise to CNP-22 and its N-terminally elongated form, CNP-53. The CNPs shar

BNP-45 (rat) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.

Mouse Brain Natriuretic Peptide-45 (BNP-45, mouse) is a circulating variant of the mouse brain natriuretic peptide derived from the mouse heart. It exhibits powerful hypotensive and natriuretic properties.

Brain natriuretic peptide-32 (BNP-32), a fragment of the proBNP cardiovascular hormone precursor, exhibits affinity for natriuretic peptide receptors in rat vascular smooth muscle cells (IC50 = 7.3 nM) and promotes cGMP accumulation within these cells (EC50 = 170 nM). Additionally, BNP-32 effectively mediates the relaxation of norepinephrine-precontracted isolated rat aortic strips (EC50 = 6.7 nM). Upon administration at a dosage of 3 µg/kg, it elevates urine and urinary electrolyte outputs and induces hypotension in rats.

Atrial Natriuretic Peptide (1-28), rat is the major circulating form of ANP in rats.

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA), is a 22 amino acid fragment of CNP and functions as an agonist for the natriuretic peptide receptor B (NPR-B). It can inhibit cAMP synthesis, which is induced by histamine, 5-HT, or Forskolin. Additionally, CNP exhibits strong endothelial-derived relaxation properties and acts as a growth inhibitor.

Auriculin B (ANP (126-150) (Rat)), a rat-derived atrial natriuretic peptide, exhibits potent vasodilatory and diuretic properties [1].

Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. It is an agonist of natriuretic peptide receptors (NPRs), with Kd values of 7.3 and 13 pM for NPR-A and NPR

Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner.

Carperitide, a 28-amino acid hormone known as Atrial Natriuretic Peptide (ANP) (1-28), is naturally synthesized and released by the human heart in reaction to cardiac injury and mechanical stretch. This compound effectively suppresses endothelin-1 secretion in a dose-dependent manner.

Atrial Natriuretic Peptide (ANP) (1-28),rat (TFA) is the main circulating forms of Atrial Natriuretic Peptide (ANP) in rats, which strongly inhibit the secretion of Ang II - stimulated endothelin-1.

Acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body\'s sa

BNP-45 (rat) TFA is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.

Atrial natriuretic factor (1-28) from both human and porcine sources is a powerful suppressor of pro-opiomelanocortin (POMC) mRNA, while it only has a modest inhibition effect on βEP-LI release.

BNP (1-32), human is a brain natriuretic peptide

Crustacean Cardioactive Peptide Acetate (CCAP acetate) is is the most conserved and ubiquitous neuropeptide in arthropods and is produced in insects by a network of conserved neurons in the ventral nerve cord.Crustacean Cardioactive Peptide Acetate is a cyclic amidated natriuretic peptide hormone commonly found in insects, crustaceans and other arthropods.

Atrial Natriuretic Peptide (ANP) has the sequence of H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, is a 28 amino acid peptide. ANP is a powerful vasodilator, and a protein (polypeptide) hormone secreted by heart muscle cells. It is involved in the hom

M65 is a PAC1 receptor-specific antagonist that inhibits the secretion of atrial natriuretic peptide (ANP) [1].

Vosoritide (BMN 111), a modified recombinant C-type natriuretic peptide (CNP) analogue, engages with natriuretic peptide receptor type B (NPR-B) to diminish the function of fibroblast growth factor receptor 3 (FGFR3). This compound is employed in the study of achondroplasia and dwarfism [1] [2] [3].

CNP-38 is a C-type natriuretic peptide (CNP) analog.

BNP (1-21), Pro (Human) is a 21-amino acid peptide and a form of B-Type Natriuretic Peptide (BNP), a cardiac natriuretic hormone. It coexists with the homologous atrial natriuretic peptide in the heart's dual natriuretic peptide system. BNP plays a critical role in heart organogenesis and the transition to extrauterine life [1] [2] [3].

Big endothelin-1 (rat 1-39), a 39-residue peptide, induces a diuretic and natriuretic response in conscious Sprague-Dawley rats and elevates blood pressure in mice [1].

PL-3994, a natriuretic peptide receptor-A (NPR-A) agonist resistant to neutral endopeptidase, functions as a bronchodilator, eliciting a concentration-dependent relaxation of pre-contracted guinea-pig trachea, evidenced by an IC50 of 42.7 nM [1].

AP 811, a selective antagonist of the atrial natriuretic peptide clearance receptor (APN-CR, NPR3) with a K i value of 0.48 nM, exhibits remarkable selectivity for NPR3 over NPR1 by more than 20,000-fold. Moreover, AP 811 effectively eliminates ANP-induced pump stimulation.

Atriopeptin III (rat) (ANP 127-150), a 24-amino acid atrial peptide, functions as a powerful vasodilator and natriuretic/diuretic agent, enhancing renal functions and reducing blood pressure in a rat model with ureter-obstructed kidneys. It is utilized in research concerning chronic renal failure [1].

AP 811 acetate is a selective antagonist of the atrial natriuretic peptide clearance receptor (ANP-CR, NPR3), demonstrating high affinity with a K_i value of 0.48 nM and exhibiting over 20,000-fold selectivity for NPR3 compared to NPR1. It effectively inhibits ANP-induced pump stimulation [1] [2].

Uroguanylin-15 (Rat) is a bioactive natriuretic peptide hormone that modulates sodium excretion in response to high NaCl intake by activating guanylate cyclase signaling pathways in the intestine and kidney. Initially isolated from rat urine and duodenum, it shares functional similarities with guanylin but has not been detected in rat colon extracts.

A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells.

Vasonatrin Peptide (VNP) TFA, a chimeric compound derived from atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), exhibits venodilating properties reminiscent of CNP, natriuretic effects akin to ANP, as well as unique arterial vasodilating capabilities not characteristic of either parent peptide. Additionally, VNP TFA confers cardioprotection in diabetic ischemia-reperfusion injury by attenuating endoplasmic reticulum (ER) stress through the cGMP-PKG signaling cascade [1] [2] [3].

Vosoritide acetate (BMN 111) is a natriuretic peptide receptor 2 (NPR2) agonist that promotes bone growth by influencing the proliferation and differentiation of chondrocytes [1].

ANP (1-30), frog, a peptide fragment sourced from atrial natriuretic peptide of frog origin, exhibits natriuretic, diuretic, and vasorelaxant properties.

Cenderitide, a natriuretic peptide (NP) that combines C-type natriuretic peptide (CNP) with the C-terminus of Dendroaspis natriuretic peptide (DNP), serves as a potent agonist of the particulate guanylyl cyclase receptor (pGC). By activating both pGC-A and pGC-B receptors, it stimulates the production of the second messenger cGMP, suppresses aldosterone, and maintains glomerular filtration rate (GFR) without affecting blood pressure. This compound is particularly significant in the context of heart failure research, as evidenced by references [1] [2] [3].

A-71915 (TFA) is a selective atrial natriuretic peptide-receptor (ANP receptor) inhibitor that promotes apoptosis and reduces insulin secretion in RINm5F pancreatic β-cells [1].

Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.